Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;11(9):5495-5499.
doi: 10.4103/jfmpc.jfmpc_2223_21. Epub 2022 Oct 14.

Association between high-sensitivity-CRP and liver elastography and cardiac ischemic diseases in patients with fatty liver

Affiliations

Association between high-sensitivity-CRP and liver elastography and cardiac ischemic diseases in patients with fatty liver

Morteza Nayebi et al. J Family Med Prim Care. 2022 Sep.

Abstract

Objective: Inflammatory markers are among the possible contributing factors with a proposed role in hepatic and ischemic heart disease. The present study aimed to determine the association between high-sensitivity-C-reactive protein (hs-CRP), liver elastography, and cardiac ischemic diseases in patients with fatty liver.

Methods: In this cross-sectional comparative study, 103 consecutive patients with fatty liver were enrolled to undergo angiography. They were divided into groups with and without cardiac ischemia.

Results: The results demonstrated that the mean hs-CRP was 2.3 and 10.9 mg/L in normal and ischemic angiography groups, respectively (P = 0.001). According to the receiver operating characteristic (ROC) analysis, the predictive role for hs-CRP was 94.5% that had sensitivity and specificity of 95.2% and 90%, respectively, with a cut-off point of 3.1.

Conclusion: This study showed that there is an association between the fatty liver, cardiac ischemia, and hs-CRP level.

Keywords: Cardiac ischemia; elastography; fatty liver; hepatic fibrosis; hs-CRP.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:8393–409. - PMC - PubMed
    1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease:Old questions and new insights. Science. 2011;332:1519–23. - PMC - PubMed
    1. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content:Prevalence of hepatic steatosis in the general population. Am J PhysiolEndocrinol Metabol. 2005;288:E462–E8. - PubMed
    1. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. ClinLiver Dis. 2009;13:511–31. - PubMed
    1. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Aweighty connection. Hepatology. 2010;51:1820–32. - PubMed